The morbidity and mortality of chronic hepatitis C is related to progressive fibrosis and the development of cirrhosis. The development of fibrosis in patients with HCV is highly influenced by immune status, host response to the virus and associated factors, such as, age, sex, alcohol intake, diabetes, obesity and coinfection with other viruses. The rate of fibrosis progression differs depending on several factors, including the stage of fibrosis and the time since infection. Routine assessment of fibrosis through biopsy every 3-5 years has poor patient acceptance and reliability, and might result in missed opportunities to improve or modify treatment priorities. Enhanced understanding of the pathophysiology of liver fibrosis in HCV infection has led to the development of a number of non-invasive assessment modalities. The ideal test would discriminate fibrosis in the categories none/early (stages 0/1), intermediate (stage 2) and advanced fibrosis/cirrhosis (stages 3/4) and be readily available, inexpensive and accurate. Biomarker tests utilize individual or combined serum markers to determine the degree of fibrosis. Other strategies combine biomarkers with clinical variables, such as patient age or utilize liver imaging or functional assessments. Incorporation of appropriately validated non-invasive assessments of liver fibrosis will likely improve the clinical care of patients with HCV infection.
Infection with HCV is a major cause of chronic liver disease, affecting 170 million people worldwide [1] [2] [3] . Chronic hepatitis C adversely affects the quality of life in a manner that is inversely proportional to the degree of fibrosis [2, 4, 5] . The adverse effect of chronic hepatitis C on the liver is a result of fibrosis progression, which can result in cirrhosis, liver failure, hepatocellular carcinoma, liver transplantation and death [1] . In addition, chronic HCV infection is sometimes associated with extrahepatic disorders, such as systemic vasculitis, rheumatic (arthralgia, myalgia and paresthaesia) and cutaneomucous (pruritus, sicca syndrome and Raynaud's phenomenon) conditions, as well as fatigue [1] .
This paper reviews the literature on fibrosis progression in chronic hepatitis C, with particular emphasis on pathophysiology, risk factors and strategies for staging and monitoring fibrosis.
Pathophysiology
Fibrosis is defined as a structural change in the liver accompanied by chronic injury. Fibrosis results in increased extracellular matrix formation and consequently increased liver stiffness [6] . The precise way in which HCV promotes liver fibrosis is unclear, but it involves a complex interplay between immunity, inflammation, apoptosis, stellate cell activation and possibly iron [7] [8] [9] [10] .
The initial response to hepatic injury results in parenchymal regeneration and predominantly periportal extracellular matrix deposition. As injury persists, the extracellular matrix components, such as collagen, proliferate and fibrillar collagen is deposited [7] . Extracellular matrix proliferation is mediated by collagens I, III and IV, fibronectin, undulin, elastin, laminin, hyaluronan and proteoglycans. The primary
Review
Perspectives on fibrosis progression in hepatitis C: an à la carte approach to risk factors and staging of fibrosis Thierry Poynard 1 , Nezam H Afdhal Introduction matrix-generating cells are the hepatic stellate cells. The secretion of collagen by hepatic stellate cells occurs in response to host inflammatory activity, specifically lymphocyte and polymorphonuclear cells. As production of matrix molecules increases, the extracellular matrix thickens, while degradation, which is mediated by matrix metalloproteinases, decreases [5] . Once hepatocyte destruction begins to outpace proliferation, apoptosis increases and the apoptotic cells are engulfed by hepatic stellate cells and Kupfer cells, a process that further activates the hepatic stellate cells to produce the inflammatory mediators, transforming growth factor (TGF)-β and collagen [11] . Apoptosis is also affected by the level of reactive oxygen species, which serve as profibrogenic substances [11, 12] .
Inflammatory mediators and cytokines, including interleukin (IL)-1, -2, -4, -6, -8, -10 and -12, tumour necrosis factor (TNF)-α and -β, interferon (IFN)-γ, and TGF-α and -β are important factors in fibrosis development [13] . TGF-β is stimulated by collagen and fibrinogen to directly stimulate proliferation of fibroblasts and to inhibit growth of hepatocytes and T-cells [7, 13] . The associated inflammatory mediators are central to fibrosis development and progression [7] . The inflammatory genes, as well as the genes controlling apoptosis (that is, Bcl and FAS), fibrosis (that is, TGF-β), vasoactive substances (that is, angiotensin II and norepinephrine) and adipokines (that is, leptin and adiponectin) are subject to polymorphism, which might explain some of the individual variation in time to fibrosis [7, 14] .
Role of HCV and the immune response in fibrosis
The progression of fibrosis is mediated by signalling molecules, cytokines, oxidant stress and intracellular molecules because of the direct effects of HCV and the associated host response, leading to necrosis, fibrosis and ultimately cirrhosis ( Figure 1 ) [8, 15] . The process of fibrosis is directly and indirectly related to HCV. Viral replication leads to infiltration of inflammatory cells (both HCV-specific and non-specific). Cytokine production activates stellate cells and promotes apoptosis. Viral proteins cause oxidative stress, increasing formation of reactive oxygen species (ROS) and interfering with antioxidant pathways, thereby leading to apoptosis. HCV also promotes steatosis, another promoter of fibrosis. In addition, genetic polymorphisms in several pathways and environmental factors, such as iron overload and alcohol, all contribute. CCR5, CC-chemokine receptor 5; COX, cyclooxygenase; CTGF, connective tissue growth factor; HLA, human leukocyte antigen; IFN, interferon; IL, interleukin; MMP, matrix metalloproteinases; NS, non-structural; PPAR, perixosome proliferator-activated receptor; TGF, transforming growth factor; TNF, tumour necrosis factor. Adapted with permission from John Wiley & Sons, Inc. [15] .
Fibrosis probably initiates with the first response to infection, that is, the innate immune response [16] . Natural killer cells have two main actions: release of the antiviral IFN-γ and major histocompatibility complex-independent cytolysis. IFN-γ release represents what is known as the T-helper (TH)1 type response and is dependent on the stimulation of natural killer cells by IFN-α, IFN-β and IL-12, which also trigger TNF-α and chemokines [16] . The degree of shift between TH1 and TH2 response could greatly alter the degree of viral persistence and the course of infection [16] . Different TH1/TH2 (IL-4 and IL-10) messenger RNA (mRNA) cytokine profiles have been noted in the peripheral blood mononuclear cells of patients with chronic hepatitis C (higher IFN-γ, IL-2 and IL-4 levels) versus self-limited disease (higher IL-10 levels) [17] .
Studies conducted in immunosuppressed patients with HIV or after liver transplantation have demonstrated enhanced fibrosis progression, which suggests a direct role of HCV on fibrosis [18] . HCV has demonstrated the ability to escape IFN antiviral activity and to inhibit IFN production. HCV non-structural protein NS3/4A serine protease blocks phosphorylation and the action of IFN regulatory factor-3, which might promote viral persistence and reduce effectiveness of IFN therapy [19, 20] . This process occurs through the ability of HCV NS3/4A to block retinoic-acid-inducible gene I, Toll-like receptor 3 and Toll-IL-1 receptor domains containing adaptor-inducing IFN-β signalling [20] . In addition, viral protein/core protein blocks signalling through the IFN receptor, NS5A protein attenuates IFN by inducing IL-8 production and E2 inhibits additional signalling pathways [20] .
In addition to effects on the host immune system, HCV core and non-structural proteins activate hepatic stellate cells, the main collagen-producing cells in the liver [7, 12] . The interaction of hepatic stellate cells with HCV is facilitated by hepatic stellate cell expression of the HCV receptor CD81, the low-density lipoprotein receptor and the c1q receptor [12] . In turn, the activated hepatic stellate cells are fibrogenic and secrete TGF-β and produce collagen [7, 12] . This process occurs because the interaction of activated hepatic stellate cells with HCV proteins increases intracellular calcium and reactive oxygen species and stimulates intracellular signalling pathways [12, 21] .
The role of hepatic steatosis and iron
The association of HCV core protein with lipid droplets and endoplasmic reticulum drives viral budding and steatosis ( Figure 2 ) [22, 23] . Steatosis is a histological finding that is associated with increased fat content of the liver, occurring in approximately 50% of patients with chronic hepatitis C [24] . In patients with HCV, steatosis is associated mainly with HCV genotype 3, metabolic factors (obesity, dyslipidaemia, diabetes mellitus and insulin resistance), alcohol consumption and drugs (such as corticosteroids) [25] [26] [27] [28] . As mentioned previously, the HCV core protein stimulates steatosis through involvement in lipid metabolism and the endoplasmic reticulum [23] . On the basis of knockout mice models, this appears to be dependent on perixosome proliferator-activated receptor (PPAR)-α activation [29] ; however, human studies have suggested lower than normal levels of PPAR-α mRNA in HCV infection [23] .
The controversy surrounding the causative relationship between steatosis and fibrosis might depend on the populations studied. Patients with diabetes also had no association between steatosis grade and cirrhosis, whereas non-diabetics had an association between steatosis and cirrhosis [30, 31] . Insulin resistance in HCV does not appear to be caused by adipocytokines (TNF-α, IL-6 and leptin adiponectin) to a more significant extent than in healthy controls [32] .
Increased serum ferritin has been noted to be a risk factor for steatosis and hepatic iron deposition appears to coexist with diabetes in HCV [33] . It is possible that insulin resistance, high glucose levels and diabetes, all of which are independently fibrogenic, are causative and that steatosis is a surrogate marker [34, 35] . However, a meta-analysis of individual data in 3,068 patients showed that steatosis was independently associated with fibrosis in a manner that is dependent on the presence of a chronic inflammatory state [27] . This was supported by a paired biopsy study, which demonstrated that both steatosis and increased alanine aminotransferase levels have a strong independent effect on fibrosis progression in antiviral non-responders [36] .
Among patients with sustained virological response (SVR), the role of steatosis in the non-regression of fibrosis and in the late occurrence of hepatocellular carcinoma must be analysed. A meta-analysis demonstrated that patients with an SVR were unlikely to progress to cirrhosis (1%) or hepatocellular carcinoma (0%) by the 5-year follow-up [37]; however, SVR is not sufficient to exclude complications, including hepatocellular carcinoma, in patients with chronic hepatitis C [38] . Studies evaluating the role of iron in HCV-induced liver fibrosis and response to treatment either failed to confirm [39] [40] [41] [42] [43] or confirmed [43] [44] [45] [46] a relationship. One of these studies demonstrated an association of iron with severe fibrosis, without an association to treatment response [43] . Nevertheless, it is likely that there is a role of iron in the development of fibrosis because there is a rational mechanism for hepatic iron accumulation in the presence of HCV. Reactive oxygen species present during HCV infection down-regulate hepicidin, which in turn leads to increased duodenal iron transport and release of iron from macrophages, resulting in hepatic iron accumulation [47] . The role of iron in HCV recently has been reviewed in detail [10] .
Genetic factors and fibrosis
Many of the apoptotic, inflammatory, vasoactive and adipokine genes are subject to polymorphism, which might explain individual variation in time to fibrosis. Polymorphisms of TGF-β1, angiotensinogen, human leukocyte antigen-II haplotypes, TNF-α, microsomal epoxide hydroxilase, haemochromatosis gene, apolipoprotein E, transporter associated with antigen processing-2, keratin, hyperhomocysteinaemia, the MTHFR 677T polymorphism, DEAD box (DDX5 minor allele) or DDX-POLG2 haplotypes, SLC11A1 promoter gene, IL-10 promoter and the MCP-1 gene have all demonstrated an effect on the progression of fibrosis in HCV [14, 48] . Among the most well-studied polymorphisms, the DDX5 missense single nucleoside polymorphism was verified in two cohorts to be associated with advanced fibrosis, whereas carnitine palmitoyltransferase 1A was linked to decreased fibrosis in those cohorts [48, 49] . Serial gene expression studies have also elucidated differences in gene clusters associated with different stages of fibrosis, yet similar to our understanding of the pathophysiology of fibrosis and the polymorphism studies, the gene clusters indicated important factors involving the extracellular matrix, inflammation, lipid biology, steroid metabolism, 
Figure 2. Interactions of HCV and hepatocytes
The proteins of HCV can activate inflammation, steatosis and fibrogenesis, and can regulate apoptosis. The core protein, NS3 and NS5A can interact with mitochondria and increase the formation of reactive oxygen species (ROS); however, only the core protein and NS5A can associate with endoplasmic reticulum and Golgi apparatus membranes, enhancing intracellular lipid accumulations by means of apolipoprotein A (ApoA)-I or -II interactions. These interactions cause inhibitions of lipid transfer protein or a defective synthesis of very low-density lipoprotein (VLDL) cholesterol. In addition, core protein can induce nuclear factor-κB (NF-κB) and cytochrome P (CYP)450 A4, promoting lipid peroxidation, ROS formation and mitochondrial damage. Overall, HCV proteins induce lipid accumulation and degradation with consequent derangement of lipid metabolism. ROS leads to induction of transforming growth factor (TGF)-β, which promotes fibrogenesis. CDK, cyclin-dependent kinase; LT-βR, lymphotoxin β-receptor; PPAR, perixosome proliferator-activated receptor; RXR, retinoid X receptor; STAT, signal transducer and activator of transcription; TNF, tumour necrosis factor; UTR, untranslated region. Adapted by permission from Macmillan Publishers Ltd: Cell Death and Differentiation [23] , copyright 2003.
amino acid metabolism, insulin signalling and glucose metabolism [50] . To a similar extent, proteomic analyses have indicated that candidate proteins increased (α 2 -macroglobulin, haptoglobin and albumin) or decreased (complement C-4, serum retinol binding protein, apolipoprotein A-1 and two forms of apolipoprotein A-IV) in advanced fibrosis [51] .
Independent risk factor profile
There are a number of well-established risk factors for accelerated progression of fibrosis to cirrhosis [1, 27, [52] [53] [54] [55] . Based on these risk factors, patients generally can be classified as high risk or low risk for developing advanced fibrosis (Table 1) [18, 27, 56] . Established factors independently associated with fibrosis progression are age, duration of infection, consumption of alcohol >50 g/day, HIV coinfection, CD4 + T-cell count <200 cells/ml, metabolic factors (body weight, body mass index, steatosis, waist circumference and fasting glucose), male gender and necrosis. Median time from HCV infection to cirrhosis can range from 5 to >50 years according to the combination of these risk factors. For example, extremely rapid progression would be expected in male heavy drinkers coinfected with HIV at the age of 50 years and extremely slow progression in females infected at birth.
Less than 50% of the variability in fibrosis progression is explained by these identified factors according to the square of correlation coefficient in multivariate modelling. Among the factors more recently identified, two seem to be independently associated with fibrosis progression: cannabis consumption [57] and schistosomiasis coinfection [58] . The exact weight of these two factors after taking into account the other factors is still unknown, but the epidemiological associations are reinforced by studies demonstrating rational mechanisms. For instance, cannabinoid CB1 receptors enhance liver fibrogenesis and steatogenesis by distinct mechanisms, therefore strongly supporting the epidemiological findings [57] .
Dynamic of fibrosis progression: linear or non-linear?
Liver assessments are staged by fibrosis scores using a variety of scoring systems (Table 2 ) [18] . The Metavir system is well validated and is most commonly used to assess fibrosis progression [52, 56] . Studies evaluating the natural progression of fibrosis have demonstrated that 27-41% of patients progress at least one fibrosis stage in 2.2-6.5 years [56, 59] . Evidence suggests that there are different phenotypes of fibrosis progression based on the presence of influencing risk factors [7, 18, 56] . Evidence also suggests that progression might be accelerated after the intermediate stage, F2, in a non-linear fashion [16] .
A recently published meta-analysis used a validated Markov maximum likelihood method on data from 111 studies in non-treated patients (n=33,121) with HCV. The meta-analysis and meta-regression demonstrated that the estimated annual mean fibrosis progression rate (95% confidence interval) was stagespecific and non-linear in a random effects model [60] . The identified stage-specific transition probabilities were F0→F1 0.117 (0.104-0.130), F1→F2 0.085 (0.075-0.096), F2→F3 0.12 (0.109-0.133) and F3→F4 0.116 (0.104-0.129). According to the metaanalysis, progression to cirrhosis accelerates, with a 20-year predicted rate of 14-16% and a 30-year rate of 37-41% [60] ; however, many biases related to patient selection and biopsy limitations are possible. It is now feasible, using validated biomarkers, to design prospective studies in larger populations with repeated fibrosis estimates.
Advances in understanding the mechanisms and natural history of fibrosis have broken ground for new diagnostic and treatment options [8] . Understanding the mechanisms of fibrosis and non-invasive staging methods will likely have a dramatic effect on the outcome of chronic HCV with fibrosis. 
Monitoring modalities using biopsy
Biopsy is considered the gold standard for assessing and monitoring liver disease associated with HCV and has been of tremendous value in enhancing clinicians' understanding of the pathology, progression and disease course [61] . It is currently recommended that liver disease associated with HCV be reassessed with liver biopsy every 3-5 years [59] . Paired biopsy studies have contributed significantly to what is known about the progression of fibrosis. In one study, patients without antiviral treatment and with mild liver disease were assessed at a median 2.5 years between biopsies. One-third of these patients demonstrated fibrosis progression of at least one point on the Ishak score, which was predicted by older age at first biopsy and presence of any fibrosis on first biopsy [62] . In another paired biopsy assessment at a mean interval of 48 months, also performed in patients without treatment, fibrosis progression based on Metavir classification occurred in 31% and was predicted by worsening steatosis, whether or not steatosis was present at baseline [63] . In a third study of untreated patients, performed at a mean 41 months between biopsies, 5% had progressed at least two fibrosis stages and 57% progressed at least one stage on an unspecified 0-5 scale. The progression of fibrosis was predicted by baseline fibrosis, steatosis and age, with alcohol intake as an important cofactor [64] . In HIVcoinfected patients not receiving anti-HCV treatment assessed with paired biopsies at a mean 49 months apart, 28% of the population progressed by at least two Metavir fibrosis score points. The second biopsy qualified 45% of patients for anti-HCV therapy despite high CD4 + T-cell counts [65] . A paired biopsy study assessing samples with approximately a 2-year delay between the paired biopsies in HIV-coinfected patients, in which some patients were treated with anti-HCV therapy, demonstrated that regression or stabilization of Ishak-score-derived fibrosis progression was possible when treated with pegylated interferon (PEG-IFN)-α2a relative to no treatment or standard IFN. In that study, patients with no treatment had a time-to-cirrhosis decrease from 22.7 to 9.09 years and a fibrosis progression rate of 0.5, which was similar to the rate in IFN-treated patients (0.5) but greater than in the PEG-IFN-α2a group (-0.1) [66] .
Interestingly, the results of a simultaneous paired biopsy performed in patients with chronic hepatitis C, in which the left and right liver lobes were evaluated at the same time, demonstrated patchy fibrosis on the Ludwig scale, with differences in one grade or one stage between lobes in 30% of patients [67] . This demonstrates a limitation to biopsy: sampling and observer variability [67] . Indeed, there are a number of limitations to biopsy in patients with HCV. A systematic review documented that more than half of the published samples failed to meet the minimum size requirement of 20-25 mm [68] ; thus, biopsy specimens do not detect small changes in fibrosis because of inadequate sample size, sampling errors, and intra-and interobserver discrepancies [68, 69] . Furthermore, biopsies are not dynamic and only evaulate an isolated area [67, 69] . Attempts to achieve an adequate sample might result in the need to have extra passes and a larger needle size, which might increase the complication rate [68] . The process of scheduling and obtaining a biopsy causes the patient physical and mental discomfort and results in a high refusal rate, morbidity and risk of mortality [69] . Although the reliability of biopsy might be improved by morphometric analysis, the sampling error is not eliminated and there is much interest in alternative diagnostic methods [70] .
The paired biopsy studies document either significant fibrosis progression or incorrect initial staging caused by sampling error during or before recommended biopsy follow-up, particularly in untreated patients. Assessment of biopsies has also validated that HIV-coinfected patients have a more rapid disease progression. Furthermore, infrequent biopsies might be unreliable because of sampling variability, which might lead to unadvisable treatment decisions.
Monitoring modalities using non-invasive biomarkers
Because of the limitations of biopsy, use of less invasive diagnostic/staging tools will yield more patient and provider satisfaction and make assessment more routine. This has been somewhat controversial, but recent evidence suggests a transition to non-invasive methods [71] [72] [73] [74] [75] . An overview by French health authorities officially approved two non-invasive biomarkers, FibroTest (FibroSure™ in the US) and FibroScan ® (Echosens, Paris, France), as first-line estimates of fibrosis in patients with chronic hepatitis C, recommended reimbursement by social security and approved liver biopsy only as a second-line estimate in case of discordance or non-interpretability of non-invasive markers [74] .
Non-invasive liver assessment methods use knowledge about the pathophysiology of fibrosis and incorporate markers of liver function, inflammation, extracellular matrix, cytokines and genes to determine the presence and severity of fibrosis [75] . The ideal test would discriminate between all Metavir stages, with a small rate of false-positive and false-negative results, be readily available and would not be expensive [75] [76] [77] .
Several general types of candidate tests have been studied, including biomarkers, combinations of biomarkers and clinical information, imaging techniques and devices, and functional assessment.
A total of 14 validated serum biomarkers (with at least two published validations) have been identified between 1991 and 2008 [75, [77] [78] [79] . Of these, 9 were not patented (PGA index, AP index, Bonacini index, Pohl score, Forns index, APRI index, MP3 index, FIB4 and FibroIndex) and 5 were patented (FibroTest, FibroSpect II, ELF, FibroMeter and HepaScore). Among these panels, the number of components combined ranged from 2 to 7 (Table 3 ) [78, [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] .
In patients with chronic hepatitis C, two biomarkers have been extensively validated, FibroTest in 4,600 patients and APRI in 4,266 patients [77, 78, [94] [95] [96] . In direct comparisons in the same patients, the accuracy of FibroTest (area under the receiver operating characteristic curve [AUROC]=0.83) for the diagnosis of advanced fibrosis (stage F2, F3 and F4 versus stages F0-F1) was higher than that of APRI (AUROC=0.76; P<0.0001) [97] . There are a few direct comparisons between patented biomarkers without significant differences among them [86] . Indirect comparisons are hazardous mainly because of the importance of spectrum bias [98] .
Several imaging devices have been used, primarily to determine the presence of severe fibrosis, including ultrasonography, computed tomography and magnetic resonance imaging [99] . FibroScan ® , which measures transient elastography, a measure of liver elasticity, also has been studied to evaluate the degree of liver fibrosis [69, [100] [101] [102] . One study on a small number of patients demonstrated better interrater agreement for determining significant fibrosis than FibroTest in HCV carriers with normal or near normal aminotransferases [103] ; however, 100% accuracy seems doubtful and studies of greater sample have not reproduced these findings in patients with normal transaminases [25, 104, 105] . Systematic reviews of FibroScan ® and FibroTest in all patients with chronic hepatitis C demonstrated similar accuracy of the two assessment methods, particularly if AUROCs were standardized according to prevalence of stages defining advanced and non-advanced fibrosis [78, 79, 96, 98, 102, 106] . Several meta-analyses have observed FibroScan ® AUROCs for advanced fibrosis between 0.83 and 0.89 [96, 106] .
In studies with at least two repeated estimates of fibrosis per patient using biomarkers with at least two studies and a control group, both FibroTest and FibroScan ® have demonstrated concordance between fibrosis progression estimated either by biopsy or non-invasive means. For FibroScan ® , there was a possible overestimation of the fibrosis regression during the first weeks of treatment because of the association between liver stiffness measurements and hepatic inflammation [96, [106] [107] [108] [109] [110] [111] [112] .
Maintenance therapy and fibrosis progression
The role of maintenance antiviral therapy in hepatitis C non-responders has been recently reviewed [113] . Three major trials, the Hepatitis C Antiviral LongTerm Treatment Against Cirrhosis (HALT-C) trial [114, 115] Table 3 . Serum markers of hepatic fibrosis with at least two validations in liver diseases
Adapted with permission from Elsevier, Inc. [78] . ALT, alanine aminotransferase; Apo, apolipoprotein; AST, aspartate aminotransferase; A2M, α2-macroglobulin; GGT, γ-glutamyltransferase; HA, hyaluronic acid; MMP, matrix metalloproteinases; PIIINP, procollagen III aminopeptide; TIMP, tissue inhibitors of metalloproteinases.
Hepatitis C Cirrhosis (EPIC) trial [116] and the Colchicine versus Peg-Intron Long Term (CoPilot) trial, evaluated maintenance antiviral therapy in patients for whom previous IFN and/or ribavirin treatment had failed [117] . After 3.5 years of follow-up, the HALT-C trial demonstrated a lack of effect of PEG-IFN-α2a 90 µg/week (34.1%) versus no treatment (33.8%; P=0.9) on the primary end point of progression of liver disease. This end point was defined as death, hepatocellular carcinoma or hepatic decompensation, or an increase in Ishak fibrosis score of two or more points for patients with baseline bridging fibrosis; however, there was a significant reduction in HCV RNA, serum aminotranferases and histological necroinflammatory scores [114] . The study was limited by lack of adherence [118] and, most importantly, by a potential lack of power [118] . The EPIC study, which used PEG-IFN 1.5 µg/kg/week in combination with ribavirin, identified several predictors of response defined as SVR. These were identified by previous treatment and response, genotype 2/3 versus 1, baseline viral load (≤600,000 versus >600,000 IU/ml) and fibrosis stage (stage 2 or 3 versus 4) [116] . In the maintenance phase, the EPIC trial showed a benefit of low-dose PEG-IFN in patients with established varices where it reduced the risk of variceal bleeding. The CoPilot trial examined the primary end point of liver failure, death, transplant, variceal bleeding and hepatocellular carcinoma using PEG-IFN 0.5 µg/kg/week compared with colchicine. The study identified that disease-free survival was limited to patients with portal hypertension [117] . In none of the studies did maintenance therapy reduce the risk of hepatocellular carcinoma. These results suggest that there might be some benefit of maintenance therapy in a subset of patients with portal hypertension. None of the maintenance studies demonstrated that PEG-IFN reduced the risk of hepatocellular carcinoma. More powerful studies should be performed and non-invasive fibrosis markers could increase the power of such studies.
Perspectives
Our understanding of the pathophysiology and progression of liver fibrosis has advanced considerably in the past 10 years. The concept of host and environmental risk factors, combined with genetic predisposition, has led to the ability to clinically stratify high-risk patients for disease progression. The effect of viral eradication on short-and long-term benefits of fibrosis regression and improvements in clinical outcomes is also now apparent. In addition, the most validated non-invasive markers (for example, FibroTest and FibroScan ® ) of liver fibrosis have reached a sufficient level of accuracy to be an alternative to liver biopsy, both for the diagnosis of fibrosis and advanced fibrosis. The realization that there is no real gold standard for the staging of liver fibrosis means that new methodology must be developed using imperfect gold standards. Or, as a recent study suggests, the error in liver biopsy itself makes it difficult to discern between a perfect surrogate (which might already exist) and ones now deemed clinically unacceptable by some [119] . Waiting for a perfect gold standard is an illusion [71, 120] . Adapted methodology should use statistical convergence between imperfect gold standards [121] , analysis of discordances between imperfect gold standards [122] and prognostic analysis [123] . There is a clear need for new consensus among clinicians, radiologists and pathologists about the multimodality staging of liver fibrosis. There is an equally important need to incorporate biomarkers into clinical treatment trials and into patient cohorts to understand the potential longitudinal use of biomarkers to predict disease progression and regression and define risks of clinical outcomes. Only with a large-scale collaborative approach between clinical investigators, industry and the research community will the true potential of biomarkers reach into clinical care.
Conclusions
The development and progression of fibrosis in patients infected with HCV is associated with an adverse prognosis for the patient. The rate of fibrosis progression differs depending on the stage of fibrosis and the time since infection. The progression rate is also affected by underlying demographic characteristics and comorbidities. Routine assessment of fibrosis through biopsy every 3-5 years is associated with poor patient acceptance and reliability. An enhanced understanding of the pathophysiology of liver fibrosis in HCV has led to the development of a number of non-invasive assessment modalities. Incorporating appropriately validated noninvasive assessments of liver fibrosis will likely improve the clinical care of patients with HCV. 
